ENVISION BLOOD GLUCOSE TEST SYSTEM
Device Facts
| Record ID | K082020 |
|---|---|
| Device Name | ENVISION BLOOD GLUCOSE TEST SYSTEM |
| Applicant | Infopia Co, Ltd. |
| Product Code | NBW · Clinical Chemistry |
| Decision Date | Dec 24, 2008 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 862.1345 |
| Device Class | Class 2 |
| Attributes | Pediatric |
Indications for Use
The Envision™ Blood Glucose Testing System is for the quantitative measurement of the concentration of glucose in capillary whole blood taken from the fingertip, ventral palm, dosal hand, upper arm, forearm, calf and/or thigh by diabetic patients or health care professionals as an aid in the management of diabetes. ENVISION™ Blood Glucose Testing System is for in vitro diagnostic use and is not to be used for the diagnosis of or screening of diabetes or for neonatal use. Alternate site testing should be done during steady- state times when glucose is not changing rapidly.
Device Story
System measures glucose concentration in capillary whole blood; utilizes electrochemical amperometry via glucose oxidase enzyme and potassium ferricyanide mediator on carbon-electrode test strips. User inserts strip into meter; applies blood sample; meter generates current proportional to glucose concentration. Used by patients or clinicians in home or clinical settings. Provides quantitative glucose readings; aids diabetes management. Includes meter, test strips, control solutions, lancing device, lancets. Features no-coding technology; stores 365 test results with 7, 14, 21-day averages. Supports alternate site testing (palm, arm, leg) during steady-state glucose levels. Benefits patients by enabling self-monitoring of blood glucose levels for improved glycemic control.
Clinical Evidence
Clinical performance evaluation conducted to validate consumer and professional accuracy. Results demonstrated substantial equivalence to the predicate device. Non-clinical testing included verification and validation of software, product, and user interface requirements based on risk analysis, with pass/fail criteria aligned with the predicate device specifications.
Technological Characteristics
In vitro diagnostic system using electrochemical sensing (glucose oxidase). Components include a meter and test strips. Operates via electrical current generation proportional to glucose concentration. Software-controlled measurement and display. No specific materials or connectivity standards provided.
Indications for Use
Indicated for quantitative glucose measurement in capillary whole blood from fingertip, palm, hand, arm, forearm, calf, or thigh. For use by diabetic patients or healthcare professionals to manage diabetes. Contraindicated for neonatal use and for the diagnosis or screening of diabetes.
Regulatory Classification
Identification
A glucose test system is a device intended to measure glucose quantitatively in blood and other body fluids. Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolism disorders including diabetes mellitus, neonatal hypoglycemia, and idiopathic hypoglycemia, and of pancreatic islet cell carcinoma.
Special Controls
*Classification.* Class II (special controls). The device, when it is solely intended for use as a drink to test glucose tolerance, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
Predicate Devices
- One Touch Ultra Blood Glucose Monitoring System (k021819)
Related Devices
- K072369 — EVOLUTION BLOOD GLUCOSE MONITORING SYSTEM · Hmd Biomedical, LLC · Mar 21, 2008
- K093941 — CLEVER CHOICE MINI BLOOD GLUCOSE MONITORING SYSTEM MODEL TD-4265 · Taidoc Technology Corporation · Mar 26, 2010
- K094005 — FORA G31A/TD-4256A BLOOD GLUCOSE MONITORING SYSTEM AND FORA G31B/TD-4256B BLOOD GLUCOSE MONITORING SYSTEM · Taidoc Technology Corporation · May 5, 2010
- K093005 — FORA G72 BLODO GLUCOSE MONITORING SYSTEM/TD-4264 BLOOD GLUCOSE MONITORING SYSTEM, MODEL TD-4264 · Taidoc Technology Corporation · Feb 5, 2010
- K072854 — DIACHEX BASIC BLOOD GLUCOSE MONITORING SYSTEM, DIACHEX SUPERB BLOOD GLUCOSE MONITORING SYSTEM · Tyson Bioresearch, Inc. · Jun 30, 2008
Submission Summary (Full Text)
{0}
1
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY AND INSTRUMENT COMBINATION TEMPLATE
A. 510(k) Number:
k082020
B. Purpose for Submission:
New Device
C. Measurand:
Whole blood glucose
D. Type of Test:
Quantitative glucose oxidase
E. Applicant:
Infopia Co., Ltd.
F. Proprietary and Established Names:
ENVISION™ Blood Glucose Test System
G. Regulatory Information:
1. Regulation section:
21 CFR 862.1345, Glucose Test System
2. Classification:
Class II
3. Product code:
NBW- System, Test, Blood Glucose, Over the Counter
CGA- Glucose Oxidase, Glucose
{1}
4. Panel:
75 (Clinical Chemistry)
H. Intended Use:
1. Intended use(s):
See indications for use below.
2. Indication(s) for use:
The ENVISION™ Blood Glucose Testing System is for the quantitative measurement of the concentration of glucose in capillary whole blood taken from the fingertip, ventral palm, dorsal hand, upper arm, forearm, calf and/or thigh by diabetic patients or health care professionals as an aid in the management of diabetes. ENVISION™ Blood Glucose Testing System is for in vitro diagnostic use and is not to be used for the diagnosis of diabetes or for neonatal use. Alternate site testing should be done during steady-state times when glucose is not changing rapidly.
3. Special conditions for use statement(s):
For over-the-counter use.
Do not use neonate samples.
Inaccurate results may occur when in shock, hypotensive individuals, hyperglycemic, or hyperosmolar state, with or without ketosis.
Envision Blood Glucose Testing System is not to be used for the diagnosis or screening of diabetes.
Alternate site testing should be done during steady-state times when glucose is not changing rapidly: before meals and before bedtime. However, when blood glucose is changing, blood from the finger tip may show these changes sooner than blood from other sites.
4. Special instrument requirements:
Infopia Envision Blood Glucose Testing System
I. Device Description:
The ENVISION Blood Glucose Testing System consists of five main components: the blood glucose meter, test strips, control solutions (three levels of ENVISION control solutions), lancing device and lancets and the users manual with log book. The performance of the test
2
{2}
strips is verified by the control solutions. The controls were previously cleared in submission k051285.
# J. Substantial Equivalence Information:
1. Predicate device name(s): One Touch Ultra Blood Glucose Monitoring System
2. Predicate $510(\mathrm{k})$ number(s): k021819
3. Comparison with predicate:
| Similarities | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Detection method | Amperometry: current is generated by oxidation of reduced mediator. | Amperometry |
| Enzyme | Glucose Oxidase | Glucose Oxidase |
| Mediator | Potassium ferricyanide | Potassium ferricyanide |
| Open Stability | 3 months | 3 months |
| Weight | 42g(including battery) | 42g (with battery) |
| Test range | 20 - 600 mg/dL | 20- 600 mg/dL |
| Electrode | Carbon electrode | Carbon electrode |
| Differences | | |
| --- | --- | --- |
| Item | Device | Predicate |
| Hematocrit Range | 20 - 60% | 30 - 55% |
| Test Time | 9 seconds | 5 seconds |
| Sample Volume | 1.5uL | 1uL |
| Temperature & Humidity range | 50 -104°F | 43 - 111°F |
| | 10 - 40°C | 6 - 44°C |
| | 10 - 90% | 10 - 90% |
| Coding | No Coding | Coding |
| Memory capability | 7, 14, 21-day average and 365 tests in the memory | 14, 30-day average and last 150 tests in the memory |
| Power | 3V Li battery (CR2032×2) | 3V Li battery (CR2032) |
| Battery life | 1 year | Running 1,000 test |
| Size: LxWxH (mm) | 77x42x19 | 80x57x21 |
| Software | ENVISION™Diabetes management software | ONETOUCH® diabetes management software |
# K. Standard/Guidance Document Referenced (if applicable):
{3}
ISO 15157:2003 In vitro diagnostic test systems- Requirement for blood-glucose monitoring systems for self-testing in managing diabetes mellitus.
ISO 14971:2007 Medical devices- Application of risk management to medical devices.
IEC 60068-2-64:1993 Environmental Testing- Part 2.
IEC 61010-1:2001 Safety Requirements for electrical equipment for measurement, control and laboratory use.
IEC 61326:2002 Electrical equipment for electrical equipment for measurement, control and laboratory use.
## L. Test Principle:
The ENVISION Blood Glucose Test System is based on the measurement of glucose concentration in human blood. The principle of the test is based on the reaction between glucose in blood sample, glucose oxidase and potassium ferricyanide. The resulting product generates a current that is proportional to the glucose concentration in the sample. The test strip employs an electrochemical signal generating an electrical current that will stimulate a chemical reaction. The reaction is measured and displayed by the meter.
## M. Performance Characteristics (if/when applicable):
### 1. Analytical performance:
#### a. Precision/Reproducibility:
Within- in precision was measured with EDTA anti-coagulated venous blood samples at five different glucose concentrations. Five hundred test strips from 10 vials from a single lot were tested with 10 meters. Ten measurements for five samples (n=50) were recorded and the results are shown in the table below.
| With-in precision | | | | | |
| --- | --- | --- | --- | --- | --- |
| | Sample 1 | Sample 2 | Sample 3 | Sample 4 | Sample 5 |
| Mean | 41.5 | 79.4 | 127.6 | 204.7 | 319.3 |
| SD | 1.1 | 1.5 | 2.2 | 4.0 | 8.1 |
| CV | 2.7 | 1.9 | 1.7 | 2.0 | 2.5 |
Between-day precision was measured by measuring three levels of control materials daily for ten days (n=90) on three separate meters. The results are summarized in the able below.
{4}
| Between-day precision | | | |
| --- | --- | --- | --- |
| | Sample 1 | Sample 2 | Sample 3 |
| Mean | 49 | 108 | 296 |
| SD | 1.1 | 1.3 | 6.4 |
| CV | 2.2 | 1.2 | 2.1 |
b. Linearity/assay reportable range:
EDTA venous blood sample was spiked to form two concentrations (high and low). The two concentrations were mixed to form 14 glucose concentrations between 20.4 to $595.8\mathrm{mg / dL}$ (confirmed by YSI) then tested with the ENVISION Blood Glucose Meter and YSI. The meter displays "Low" with glucose values below $20\mathrm{mg / dL}$ , "Hi" with glucose values over $600\mathrm{mg / dL}$ . Each glucose level was measured 5 times by the ENVISION Meter and in duplicate by YSI. Regression analysis showed a linear relationship between the ENVISION Meter and the YSI method: $\mathrm{y = 0.998x - 0.880}$ , $\mathrm{R}^2 = 1$ .
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
The glucose control standards are traceable to a NIST glucose standard and were previously cleared in submission k051285. The reference instrument used is the YSI 2300 Glucose analyzer and is calibrated by YSI 2747 Glucose Standard which is a NIST traceable glucose standard. The controls are prepared at three target concentrations gravimetrically and the glucose concentrations are verified with the YSI reference method. The expected values are verified for each new lot of strips.
Shelf-life studies show that the unopened test strips have a 26 month life-span and 3 months shelf-life once a vial of strips is opened. Unopened controls have a 26 month shelf life and are stable for 3 months after first use.
d. Detection limit:
The sponsor has not conducted studies to determine the limit of detection (LOD). However, the lower limit is supported by linearity studies. The sponsor has established the measuring range of $20 - 600\mathrm{mg / dL}$ for ENVISION Blood Glucose Test System.
e. Analytical specificity:
The sponsor evaluated the effects of hematocrit on whole blood samples spiked with 4 to 5 hematocrit levels (between $20 - 60\%$ ) at eight glucose concentrations between 45 to $559\mathrm{mg}$ . These values were compared to values from an YSI-2300 analyzer. The results indicated that bias introduced at hematocrit levels between $20\%$ to $60\%$ was within $+/-15\mathrm{mg/dL}$ for values under $75\mathrm{mg/dL}$ and $+/-10\%$ for values $75\mathrm{mg/dL}$ and over.
{5}
A temperature study was conducted with three control solutions kept at room temperature. Five meters and strips were set to three different temperatures between 10 and $40^{\circ}\mathrm{C}$ . A humidity study was conducted with three glucose levels run at three humidity percentages. The results from both studies showed that the device can be used from 10 to $40^{\circ}\mathrm{C}$ and from 10 to $90\%$ relative humidity.
The sponsor conducted an altitude study to evaluate the effects of decreased oxygen pressure resulting from high altitudes may have on the device. An altitude study was performed with venous blood samples from volunteers. Glucose values of adjusting $\mathsf{pO}_2$ venous bloods (ranging from $32\mathrm{mg / dL}$ to $551\mathrm{mg / dL}$ ) were measured by ENVISION™ in the altitude chamber at sea level and 10,000 feet conditions. Glucose values of plasma centrifuged from venous whole blood were measured by YSI 2300 as the reference value. Linear regression results of the Envision versus the YSI results at 10000 feet revealed a line of $y = 0.9949 - 1.09$ and a correlation coefficient of 0.9990. The test data using the samples from both meters (sea-level and 10000 feet) showed that the bias versus YSI at 10,000 feet is the same bias versus YSI as that observed at sea level. These data indicate no additional effect due to altitude up to 10,000 feet. The results indicate that the device is unaffected by altitudes up to 10,000 feet.
Common interferences were evaluated by spiking venous blood with glucose to three concentrations based on EP7-P of low (less than $75\mathrm{mg / dL}$ ) normal ( $160\mathrm{mg / dL}$ ) and high (greater than $240\mathrm{mg / dL}$ ). Middle concentrations were prepared gravimetrically from the two initial concentrations to form 5 total concentrations. The glucose samples were spiked with the interferents and run in replicates of 5. The sponsor's acceptance criterion was $+/-15\%$ bias. There was no interference effects observed up to the high test levels show in the table below. The error% of uric acid, Dopamine and Gentistic acid was over $\pm 15\%$ , failing the criteria. Thus, uric acid, Dopamine and Gentistic acid were included as an interference in the strip user manual. The three interferences studies are shown in the three tables below.
| Interference substance | | Mean of Test Results | | |
| --- | --- | --- | --- | --- |
| Interferences | High Interference Test Level (mg/dL) | Low (mg/dL) | High (mg/dL) | Difference* (mg/dL) |
| Acetaminophen | 20 | 44.8 | 48.2 | 3.4 |
| Bilirubin | 40 | 45.8 | 48.8 | 3.0 |
| Gentistic acid | 50 | 44.8 | 53.8 | 9.0 |
| Levo-Dopa | 4 | 46.2 | 47.2 | 1.0 |
| Methyl-Dopa | 2.5 | 46.2 | 47.8 | 1.6 |
| Tolazamide | 5 | 45.8 | 46.8 | 1.0 |
| Dopamine | 13 | 44.8 | 53.4 | 8.6 |
| Ascorbate | 3 | 44.8 | 48.2 | 3.4 |
| EDTA | 640 | 44.8 | 47.0 | 2.2 |
| Glutathione | 1 | 44.8 | 49.4 | 4.6 |
{6}
Normal:
| Interference substance | | Mean of Test Results | | |
| --- | --- | --- | --- | --- |
| Interferences | High Interference Test Level (mg/dL) | Low (mg/dL) | High (mg/dL) | Difference* (%) |
| Acetaminophen | 20 | 160.6 | 160.6 | 7.3 |
| Bilirubin | 40 | 163.4 | 163.4 | 7.1 |
| Gentistic acid | 50 | 160.6 | 160.6 | 17.7 |
| Levo-Dopa | 4 | 160.8 | 160.8 | 2.0 |
| Methyl-Dopa | 2.5 | 160.8 | 160.8 | 3.1 |
| Tolazamide | 5 | 163.4 | 163.4 | 1.8 |
| Dopamine | 13 | 160.6 | 160.6 | 17.7 |
| Ascorbate | 3 | 160.6 | 160.6 | 4.1 |
| EDTA | 640 | 160.6 | 160.6 | 2.9 |
| Glutathione | 1 | 160.6 | 160.6 | 6.4 |
| Heparin | 1,000 | 160.6 | 160.6 | 2.5 |
| Ibuprofen | 40 | 161.4 | 161.4 | 10.0 |
| Salicylic acid | 50 | 160.6 | 160.6 | 3.6 |
| Tetracycline | 0.4 | 160.6 | 160.6 | 6.5 |
| Tolbutamide | 100 | 161.4 | 161.4 | 11.4 |
| Urea | 500 | 160.6 | 160.6 | 9.1 |
| Uric acid | 20 | 45.8 | 52.2 | 6.4 |
| Creatinine | 30 | 44.8 | 47.4 | 2.6 |
| Cholesterol | 500 | 46.0 | 50.2 | 4.2 |
| TG | 3000 | 45.8 | 49.6 | 3.8 |
| Glactose | 50 | 44.8 | 48.6 | 3.8 |
| Xylose | 10 | 44.8 | 49.0 | 4.2 |
| Maltose | 300 | 44.8 | 48.0 | 3.2 |
* Difference(mg/dL) = (assay value with interference substance - assay value without interference substance)
{7}
High:
| Interference substance | | Mean of Test Results | | |
| --- | --- | --- | --- | --- |
| Interferences | High Interference Test Level (mg/dL) | Low (mg/dL) | High (mg/dL) | Difference* (%) |
| Acetaminophen | 20 | 307.8 | 328.8 | 6.8 |
| Bilirubin | 40 | 304.8 | 323.2 | 6 |
| Gentistic acid | 50 | 307.8 | 358.4 | 16.4 |
| Levo-Dopa | 4 | 306.4 | 315.0 | 2.8 |
| Methyl-Dopa | 2.5 | 306.4 | 316.8 | 3.4 |
| Tolazamide | 5 | 304.8 | 313.6 | 2.9 |
| Dopamine | 13 | 307.8 | 359.2 | 16.7 |
| Ascorbate | 3 | 307.8 | 319.0 | 3.6 |
| EDTA | 640 | 307.8 | 315.8 | 2.6 |
| Glutathione | 1 | 307.8 | 324.4 | 5.4 |
| Heparin | 1,000 | 307.8 | 316.2 | 2.7 |
| Ibuprofen | 40 | 306.0 | 337.6 | 10.3 |
| Salicylic acid | 50 | 307.8 | 320.6 | 4.2 |
| Tetracycline | 0.4 | 307.8 | 325.2 | 5.7 |
| Tolbutamide | 100 | 306.0 | 337.0 | 10.1 |
| Urea | 500 | 307.8 | 333.8 | 8.4 |
| Uric acid | 20 | 304.8 | 343.0 | 12.5 |
| Creatinine | 30 | 307.8 | 324.4 | 5.4 |
| Cholesterol | 500 | 305.0 | 320.6 | 5.1 |
| TG | 3000 | 303.0 | 320.0 | 5.6 |
| Galactose | 50 | 307.8 | 323.4 | 5.1 |
| Xylose | 10 | 307.8 | 322.8 | 4.9 |
| Maltose | 300 | 307.8 | 318.4 | 3.4 |
* Difference (%) = (assay value with interference substance - assay value without interference substance) x 100 / assay value without interference substance
{8}
f. Assay cut-off:
Not applicable.
# 2. Comparison studies:
a. Method comparison with predicate device:
System accuracy was evaluated by comparing the fingertip results of 160 samples that spanned the claimed assay range to the results obtained by a Hitachi 747. Samples ranged from 30 to $507\mathrm{mg / dL}$ and were run on two different meters. For some of the samples that were less than $50\mathrm{mg / dL}$ and greater than $400\mathrm{mg / dL}$ , pooled anticoagulated capillary whole blood specimens were allowed to hydrolyze or were spiked to the desired glucose levels. Regression analysis of results from both meters is shown below:
{9}
95% of the individual glucose results were within the ISO 15197 criteria specifying that 95% of samples are within +/- 15 mg/dL when glucose concentration less than 75 mg/dL and within +/- 20% glucose concentration ≥75 mg/dL.
System accuracy results for glucose concentration < 75 mg/dL (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
| 38/56 (68 %) | 56/56(100 %) | 56/56(100 %) |
System accuracy results for glucose concentration ≥75 mg/dL (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 188/264(71%) | 245/264(93%) | 260/264(98%) | 262/264(99%) |
# Lay user studies:
The sponsor conducted a study at three clinical sites (50 users per site) to compare the accuracy of glucose measurement between the lay-user and the healthcare professionals. At each clinical site, the lay-user performed a fingerstick, tested their blood with the ENVISION meter and recorded their results. A healthcare professional then obtained a capillary blood sample and a venous sample to obtain results with the same ENVISION meter and the Hitachi 747. The lay user then completed a questionnaire to cover demographics and ease of use and understanding. Regression analysis of the participants' fingerstick value (ranged from $59 - 540\mathrm{mg / dL}$ ) against a laboratory method (Hitachi 747) yielded the following results: $y = 1.00224x$
{10}
2.392, R2=0.9843. The results (shown below the graphs) for the user versus healthcare results were within the ISO 15197 criteria of individual differences within +/- 15 mg/dL when glucose concentration less than 75 mg/dL and within +/- 20% glucose concentration ≥75 mg/dL.
ENVISION data by Lay person vs ENVISION data by professional
System accuracy results for glucose concentration <75 mg/dL (4.2 mmol/L)
| Within ± 5mg/dL
(within ± 0.28 mmol/L) | Within ± 10 mg/dL
(within ± 0.56 mmol/L) | Within ± 15mg/dL
(within ± 0.83 mmol/L) |
| --- | --- | --- |
| 18/25 (72 %) | 24/25(96 %) | 24/25(96%) |
System accuracy results for glucose concentration ≥75 mg/dL (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 93/125(74%) | 117/125(94%) | 121/125(97%) | 123/125(98%) |
The sponsor assessed readability of the labeling by the previously recruited 150 lay users who were provided with the ENVISION test kit. Participants varied in age, education, country of origin and gender. The overall survey indicated that 88% of the participants found the labeling easy to use and understand. The readability for the user manual, strip manual and control solution labeling are grades 6.5, 7.0 and 5.5, respectively.
{11}
# Alternate Site Studies (AST):
The sponsor conducted alternative site testing (AST) using the ventral palm, the dorsal hand, the forearm, the upper arm, the calf, and the thigh and compared the results to concurrent fingerstick readings. Lay-users vigorously rubbed the alternative site for 5-10 seconds (until they felt warming) before obtaining the sample. Regression results are shown below and the percentage of results meeting ISO 15197 acceptance criteria for accuracy.
| Comparison | N | Range (mg/dL) | Regression | R2 |
| --- | --- | --- | --- | --- |
| Ventral palm vs. finger | 100 | 66-488 | Y=1.0056x-1.0066 | 0.9817 |
| Dorsal hand vs. finger | 100 | 61-474 | Y=0.9795x+2.7119 | 0.9908 |
| Total hand vs. finger | 200 | 61-488 | Y=0.9932x+0.859 | 0.9862 |
| Forearm vs. finger | 100 | 62-470 | Y=0.9933x+1.3844 | 0.989 |
| Upper arm vs. finger | 100 | 59-478 | Y=1.0081x-2.6555 | 0.9884 |
| Total arm | 200 | 59-478 | Y=1.00x-0.3617 | 0.9889 |
| Calf vs. finger | 100 | 52-456 | Y=1.0044x-0.3139 | 0.9853 |
| Thigh vs. finger | 100 | 60-470 | Y=0.9881x+2.4037 | 0.977 |
| Total leg vs. finger | 200 | 52-470 | Y=0.9945+1.3495 | 0.9815 |
Data analysis with finger capillary blood and palm blood
ENVISION™ (DORSAL HAND) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
| 7/8 (88 %) | 8/8(100 %) | 8/8(100%) |
System accuracy results for glucose concentration $\geq 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 60/92(65%) | 82/92(89%) | 90/92(98%) | 91/92(99%) |
ENVISION™ (VENTRAL PALM) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
{12}
System accuracy results for glucose concentration $\geq 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 64/91(70%) | 82/91(90%) | 90/91(99%) | 90/91(99%) |
## ENVISION™ (PALM) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ± 5mg/dL
(within ± 0.28 mmol/L) | Within ± 10 mg/dL
(within ± 0.56 mmol/L) | Within ± 15mg/dL
(within ± 0.83 mmol/L) |
| --- | --- | --- |
| 16/17 (94 %) | 17/17(100 %) | 17/17(100%) |
System accuracy results for glucose concentration $\geq 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 124/183(68%) | 164/183(90%) | 180/183(98%) | 181/183(99%) |
Data analysis with finger capillary blood and arm blood
## ENVISION™ (FOREARM) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ± 5mg/dL
(within ± 0.28 mmol/L) | Within ± 10 mg/dL
(within ± 0.56 mmol/L) | Within ± 15mg/dL
(within ± 0.83 mmol/L) |
| --- | --- | --- |
| 4/9(44 %) | 9/9(100 %) | 9/9(100%) |
System accuracy results for glucose concentration $\geq 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 63/91(69%) | 88/91(97%) | 89/91(98%) | 90/91(99%) |
## ENVISION™ (UPPERARM) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ± 5mg/dL
(within ± 0.28 mmol/L) | Within ± 10 mg/dL
(within ± 0.56 mmol/L) | Within ± 15mg/dL
(within ± 0.83 mmol/L) |
| --- | --- | --- |
| 7/8 (88 %) | 7/8 (88 %) | 8/8 (100 %) |
System accuracy results for glucose concentration $\geq 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 69/92(75%) | 89/92(97%) | 91/92(99%) | 91/92(99%) |
## ENVISION™ (ARM) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
| Within ± 5mg/dL
(within ± 0.28 mmol/L) | Within ± 10 mg/dL
(within ± 0.56 mmol/L) | Within ± 15mg/dL
(within ± 0.83 mmol/L) |
| --- | --- | --- |
| 11/17 (65 %) | 16/17 (94 %) | 17/17 (100 %) |
System accuracy results for glucose concentration $\geq 75\ \mathrm{mg/dL}$ (4.2 mmol/L)
{13}
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 132/183(72%) | 177/183(97%) | 180/183(98%) | 181/183(99%) |
Data analysis with finger capillary blood and leg blood
ENVISION™ (CALF) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
| 6/6 (100 %) | 6/6 (100 %) | 6/6 (100 %) |
System accuracy results for glucose concentration $\geq 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 63/94(67%) | 89/94(95%) | 92/94(98%) | 92/94(98%) |
ENVISION™ (THIGH) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
| 5/8 (63 %) | 7/8 (88 %) | 8/8 (100 %) |
System accuracy results for glucose concentration $\geq 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 64/92(70%) | 87/92(95%) | 89/92(97%) | 90/92(98%) |
ENVISION™ (LEG) vs ENVISION™ (FINGER)
System accuracy results for glucose concentration $< 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ± 5mg/dL (within ± 0.28 mmol/L) | Within ± 10 mg/dL (within ± 0.56 mmol/L) | Within ± 15mg/dL (within ± 0.83 mmol/L) |
| --- | --- | --- |
| 11/14(79%) | 13/14(93 %) | 14/14(100 %) |
System accuracy results for glucose concentration $\geq 75\mathrm{mg / dL}$ (4.2 mmol/L)
| Within ±5% | Within ±10% | Within ±15% | Within ±20% |
| --- | --- | --- | --- |
| 127/186(68%) | 176/186(95%) | 181/186(97%) | 182/186(98%) |
b. Matrix comparison:
Not applicable; this device is only indicated for capillary whole blood
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
{14}
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable.
4. Clinical cut-off:
Not applicable.
5. Expected values/Reference range:
The normal fasting adult glucose range for a non-diabetic is 70-105 mg/dL. One to two hours after a meal, normal blood glucose levels should be less than 140 mg/dL. A medical professional should determine the range that is appropriate for diabetes patients.¹,²
¹) Krall, L.P., and Beaser, R.S.: Joslin Diabetes Manuak\ I. Philadelphia: Lea and Febiger(1989), 138
²) Beaser, R.S. and Hill, Joan: The Joslin Guide to Diabetes. New York: Simon and Schuster (1995), P158
N. Instrument Name:
ENVISION™ Blood Glucose Test System
O. System Descriptions:
1. Modes of Operation:
Each test strip is single use and must be replaced with a new strip for additional readings.
2. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:
Yes ☐ X ☐ or No ☐
3. Specimen Identification:
There is no sample identification function with this device. Samples are applied directly to the test strip as they are collected.
4. Specimen Sampling and Handling:
This device is intended to be used with capillary whole blood from the finger, ventral palm, the dorsal hand, the forearm, the upper arm, the calf, and the thigh. Since the whole blood sample is applied directly to the test strip there are no special handling or storage issues.
15
{15}
5. Calibration:
Strip lot-specific calibration is accomplished by embedding a Calibration Code onto each Envision test strip, which then provides the Calibration Code information to the Envision meter when the strip is inserted.
6. Quality Control:
The sponsor has three levels of controls available for this meter with both levels coming with the kit and also being available through the distributor. When a test strip is inserted into the meter, a control can be run. An acceptable range for each control level is printed on the test strip vial label. The user is referred to a troubleshooting section at the end of the control test instructions of the owner’s manual to identify possible reasons control results fall outside these ranges.
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The “Performance Characteristics” Section above:
None
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.
